||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Dechra Share Discussion Threads
Showing 376 to 394 of 400 messages
|a little pull back after some profit taking is probably in order. I shall continue to accumulate on any weakness.
|Agreed, Woody, could be a very lucrative deal and one for the long term.|
|and a very interesting one for the future.........if the price falls a little I will add to my 3/5 year portfolio.|
|looks like a further quality deal/acquisition
|added to my holding this morning. chart looks strong
|Getting near your £17 ............ but why not think of £20 when they announce another record year.......but not just yet!|
|Aviva up thier holding before publication of results!! Think about that........
What a good set of results and more to play for by the management.|
Still with a head of steam!|
|Whiskers and Fido rule ok.|
|been accumulating a few times since it broke thro' 1400p
|One reason why this company is a success is that the CEO has been able to create a team which is very able in extracting profits from all the acquisitions.
When a share goes up on a day like today then there is lot more good news to come over the coming year.
Well done the management ..........|
|Trading UpdateThe Board of Dechra issues the following unaudited Trading Update covering the half year reporting period (the Period) from 1 July to 31 December 2016.Highlights-- Reported Group revenue for the Period increased by approximately 34% at constant exchange rate (CER) (56% at actual exchange rate (AER)).-- Core Group revenue growth, excluding the benefit from acquisitions, was 7% at CER (AER 22%); growth in the core EU business was 6% at CER (AER 20%), and 10% (AER 31%) in North America.-- All acquisition integrations are progressing well with revenue contributions from Genera, Putney, Apex and Brovel being ahead of the Board's expectations.-- Approval by the FDA was achieved for the first major product from the Putney pipeline, a Companion Animal Product (CAP) generic antibiotic, Amoxi-clav.Ian Page, Chief Executive Officer, said:"Our underlying business and acquisitions have performed well, resulting in significant growth in the first half of the 2017 financial year. The Group pipeline has delivered new products and our global presence continues to increase. We remain confident in our strategy, our future prospects and our expectations for full year performance."|
|Bought in to the story today as a one year+ holding............|
|Been buying quite a few recently
free stock charts from uk.advfn.com|
|Time they started increasing the dividends imo.|
|Apex acquisition (Australia/NZ)and base for Asian expansion.looks very sound.The total consideration for the Acquisition, which is expected is to complete on 14 October 2016, is AUS$55.0 million (£31.3 million). This will be funded from the Group's own cash and debt resources. The acquisition is expected to be earnings enhancing in the first 12 months.|
After a strong trading update last month, full-year results from veterinary group Dechra (DPH) are unsurprising, but no less impressive. Revenues and adjusted operating profit are both up by over a fifth and three acquisitions completed in the period have enhanced the outlook. Shares are up 3 per cent this morning and we continue to see an upside. Buy.